Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial

Andres M. Poveda; Frédéric Selle; Felix Hilpert; Alexander Reuss; Antonella Savarese; Ignace Vergote; Petronella Witteveen; Aristotelis Bamias; Nana Scotto; Lada Mitchell; Eric Pujade-Lauraine

doi:10.1200/JCO.2015.63.1408;

Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial

Andres M. Poveda, Frédéric Selle, Felix Hilpert, Alexander Reuss, Antonella Savarese, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Nana Scotto, Lada Mitchell, Eric Pujade-Lauraine

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	3836-3838
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	33
Issue number	32
DOIs	https://doi.org/10.1200/JCO.2015.63.1408;
Publication status	Published - Nov 10 2015

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1200/JCO.2015.63.1408;

Cite this

Poveda, A. M., Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., & Pujade-Lauraine, E. (2015). Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial. Journal of Clinical Oncology, 33(32), 3836-3838. https://doi.org/10.1200/JCO.2015.63.1408;

Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer : Analysis by chemotherapy cohort of the randomized phase III aurelia trial. / Poveda, Andres M.; Selle, Frédéric; Hilpert, Felix; Reuss, Alexander; Savarese, Antonella; Vergote, Ignace; Witteveen, Petronella; Bamias, Aristotelis; Scotto, Nana; Mitchell, Lada; Pujade-Lauraine, Eric.

In: Journal of Clinical Oncology, Vol. 33, No. 32, 10.11.2015, p. 3836-3838.

Research output: Contribution to journal › Article › peer-review

Poveda, AM, Selle, F, Hilpert, F, Reuss, A, Savarese, A, Vergote, I, Witteveen, P, Bamias, A, Scotto, N, Mitchell, L & Pujade-Lauraine, E 2015, 'Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial', Journal of Clinical Oncology, vol. 33, no. 32, pp. 3836-3838. https://doi.org/10.1200/JCO.2015.63.1408;

Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial. Journal of Clinical Oncology. 2015 Nov 10;33(32):3836-3838. https://doi.org/10.1200/JCO.2015.63.1408;

Poveda, Andres M. ; Selle, Frédéric ; Hilpert, Felix ; Reuss, Alexander ; Savarese, Antonella ; Vergote, Ignace ; Witteveen, Petronella ; Bamias, Aristotelis ; Scotto, Nana ; Mitchell, Lada ; Pujade-Lauraine, Eric. / Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer : Analysis by chemotherapy cohort of the randomized phase III aurelia trial. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 32. pp. 3836-3838.

@article{dbae0e4d7bbc4679a7c5dda40927e3c2,

title = "Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial",

author = "Poveda, {Andres M.} and Fr{\'e}d{\'e}ric Selle and Felix Hilpert and Alexander Reuss and Antonella Savarese and Ignace Vergote and Petronella Witteveen and Aristotelis Bamias and Nana Scotto and Lada Mitchell and Eric Pujade-Lauraine",

year = "2015",

month = nov,

day = "10",

doi = "10.1200/JCO.2015.63.1408;",

language = "English",

volume = "33",

pages = "3836--3838",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "32",

}

TY - JOUR

T1 - Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer

T2 - Analysis by chemotherapy cohort of the randomized phase III aurelia trial

AU - Poveda, Andres M.

AU - Selle, Frédéric

AU - Hilpert, Felix

AU - Reuss, Alexander

AU - Savarese, Antonella

AU - Vergote, Ignace

AU - Witteveen, Petronella

AU - Bamias, Aristotelis

AU - Scotto, Nana

AU - Mitchell, Lada

AU - Pujade-Lauraine, Eric

PY - 2015/11/10

Y1 - 2015/11/10

UR - http://www.scopus.com/inward/record.url?scp=84947436029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947436029&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.63.1408;

DO - 10.1200/JCO.2015.63.1408;

M3 - Article

VL - 33

SP - 3836

EP - 3838

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 32

ER -

Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this